HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...
Health and Me on MSN1d
GLP-1 Drugs Could Be Used To Treat Chronic Kidney DiseaseA latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
People who take weight-loss drugs based on GLP-1 receptor agonists seem to have ... including sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked ...
Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of chronic obstructive pulmonary ...
HealthDay on MSN1d
Age Differences Seen in Efficacy of Type 2 Diabetes TreatmentsAge differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in ...
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, commonly used for blood sugar control, also offer benefits such as weight loss and reduced inflammation. Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback